Clinical Trial Update: Safety and Efficacy of Everolimus - Eluting Bioresorbable Vascular Scaffold for Cardiac Allograft Vasculopathy [Phase 4]

View source ↗

Summary

Phase 4 trial update on safety and efficacy of everolimus-eluting bioresorbable vascular scaffold for cardiac allograft vasculopathy has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Allograft Vasculopathy

Drugs mentioned

• Everolimus-eluting bioresorbable vascular scaffold (everolimus-eluting bioresorbable vascular scaffold)

Snippet

Sponsor: Universita di Verona | Conditions: Cardiac Allograft Vasculopathy | Phase 4 | Status: COMPLETED